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Background: Tumor formation is a complex process which involves constitutive activation of oncogenes and
suppression of tumor suppressor genes. Receptor EphA2 and its ligand ephrin-A1 form an important cell
communication system with its functional role in cell-cell interaction and tumor growth. Loss of cell-cell adhesion is
central to the cellular transformation and acquisition of metastatic potential. Claudins, the integrated tight junction
(TJ) cell-cell adhesion proteins located on the apico-lateral portion of epithelial cells, functions in maintaining cell
polarity. There is extensive evidence implicating Eph receptors and ephrins in malignancy, but the mechanisms
how these molecular players affect TJ proteins and regulate tumor growth are not clear. In the present study we
hypothesized that EphA2 signaling modulates claudin-2 gene expression via induction of cdx-2, a tumor suppressor
gene in NSCLC cells.
Methods: The expression of EphA2, claudin-2 was determined in various NSCLC cell lines by using real-time
quantitative polymerase chain reaction and Western blot analysis. The claudin-2 expression was also analyzed by
immunofluorescence analysis. EphA2 and erk1/erk2 phosphorylation in ephrin-A1 activated cells was evaluated by
Western blot analysis. The cell proliferation and tumor colony formation were determined by WST-1 and 3-D
matrigel assays respectively.
Results: NSCLC cells over expressed receptor EphA2 and claudin-2. Ephrin-A1 treatment significantly down
regulated the claudin-2 and EphA2 expression in NSCLC cells. The transient transfection of cells with vector
containing ephrin-A1 construct (pcDNA-EFNA1) decreased the expression of claudin-2, EphA2 when compared to
empty vector. In addition ephrin-A1 activation increased cdx-2 expression in A549 cells. In contrast over-expression
of EphA2 with plasmid pcDNA-EphA2 up regulated claudin-2 mRNA expression and decreased cdx-2 expression.
The transient transfection of cells with vector containing cdx-2 construct (pcMV-cdx-2) decreased the expression of
claudin-2 in A549 cells. Moreover, silencing the expression of receptor EphA2 by siRNA significantly reduced
claudin-2 expression and decreased cell proliferation and tumor formation. Furthermore, silencing cdx-2 gene
expression before ephrin-A1 treatment increased claudin-2 expression along with increased cell proliferation and
tumor growth in A549 cells.
Conclusions: Our study suggests that EphA2 signaling up-regulates the expression of the TJ-protein claudin-2 that
plays an important role in promoting cell proliferation and tumor growth in NSCLC cells. We conclude that receptor
EphA2 activation by ephrin-A1 induces tumor suppressor gene cdx-2 expression which attenuates cell proliferation,
tumor growth and thus may be a promising therapeutic target against NSCLC.
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Tight junctions (TJ), the most apical cell-cell adhesion,
owing to their cellular location are responsible for main-
taining the cellular integrity. Any deregulation of the TJ
characteristics could potentially lead to cellular transform-
ation and acquisition of tumorogenesis potential [1]. How-
ever, emerging details from many studies related with
claudin and cancer have implicated claudin family members
in a wide range of human cancers. The expression of
claudins would decrease during tumorogenesis as tight
junctions are lost during cellular transformation, but it is
understood that claudins are expressed in a tissue specific
manner [2-11]. Down-regulation of claudins in cancer
seems to be well understood, but increased expression of
claudin contributing to neoplastic progression is less clear
[1]. Aberrant tissue expression of certain claudins may con-
tribute to neoplasia by directly altering TJ structure and
function [1]. Furthermore it is also postulated that claudins
may affect cell-signalling pathways [12].
Cdx-2 is a transcriptional factor crucial to the normal
proliferation and differentiation of intestinal epithelial
cells [13], however little is known about the transcrip-
tional program that controls genes involved in NSCLC
tumor growth. In colorectal cancer reduced expression
of cdx-2 has been reported in rodents and humans
[14,15]. In addition, cdx-2 null mice embryos failed to
survive and heterozygote’s developed intestinal tumors.
Furthermore the polyps developed in the colon do not
express cdx-2 which indicates that loss of cdx-2 pro-
motes tumorogenesis [16]. Cdx-2 regulates claudin-2
functions by binding to its 5’ flanking region and affects
the expression of downstream pathway genes [17]. How-
ever, if receptor EphA2 activation with ephrin-A1
induced expression of cdx-2 plays any role in NSCLC
tumor growth is not known.
The Eph family of receptor tyrosine kinases plays key
role in the development of cancer. The Eph receptors
and ephrins were originally discovered as neuronal
guidance and vasculature formation proteins during em-
bryonic development [18]. Eph receptors and their
ligands, ephrins are often dysregulated in malignant phe-
notypes including NSCLC [19-23]. However the precise
role of these proteins in tumor growth is not well under-
stood. Defining the role of EphA2 and ephrin-A1 in
NSCLC is particularly important, as EphA2 receptor is
highly expressed in NSCLC which contributes to tumor
development. The aim of our study was to investigate
the underlying mechanisms of tumor suppressor effect
of ephrin-A1 in NSCLC. We report a novel mechanism
of ephrin-A1 mediated attenuation of NSCLC tumor
growth due to down regulation of claudin-2 and induc-
tion of tumor suppressor gene cdx-2. Thus providing the
evidence that receptor EphA2 may be a promising thera-
peutic target for NSCLC.Methods
NSCLC cell culture
A549 NSCLC cell line was obtained from American Type
Culture Collection (Manassas, VA) and NCI-H2126, NCI-
H838, NCI-H522, NCI-H23 NSCLC cell-lines were a kind
gift from Dr. Frederic Kaye, MD, Division of Haemato-
logy/Oncology, University of Florida, Gainesville, Florida.
The NSCLC cells were resuspended in RPMI-1640 (Gibco
Laboratories, Grand Island, NY) containing 10% FBS,
penicillin (100 U/ml) and streptomycin (100 μg/ml). The
cells were plated in 100 mm Petri dishes (Corning Costar
Corporation, MA) and incubated at 37°C in 5% CO2 and
95% air. The cell culture medium was changed on alter-
nate days. When the cells were confluent they were trypsi-
nized and seeded into 100 mm culture dishes or transwell
chambers as required for different assays.
Construction of vectors containing ephrin-A1 (EFN-A1)
and EphA2 and transient transfection of NSCLC cells
The gene transfer vector, pcDNA3.2/V5-DEST was used
as an expression vector for the expression of ephrin-A1
(EFN-A1), and receptor EphA2, and pcDNA3.2/V5/CAT
was used as a control vector (Invitrogen, Carlsbad, CA)
as reported earlier [24]. For the over expression of cdx-2
gene, pcMV6-XL5 was used as an expression vector for
cdx-2 and control vector in A549 cells (Origene Tech-
nologies, Inc.; Rockville, MD). The cloned vectors were
designated as pcDNA-EFN-A1, pcDNA-EphA2 and
pcMV-cdx2 respectively. The control vectors were desig-
nated as Empty vector or pcMV-control. The NSCLC
cells were transfected with vectors using lipofectamine-
2000 reagent (Invitrogen, Carlsbad, CA). The transfected
cells were used for further experiments.
Transfection of NSCLC cells
The siRNA targeting the receptor EphA2 and cdx-2 were
designed using Oligoperfect design (Invitrogen, Carlsbad,
CA). A549 cells were plated into 6-well plates or 35 mm
plates as required for the experiments. The cells were
allowed to adhere for 24 hours. The transfection of siRNA
was performed using lipofectamine-2000 (Invitrogen)
according to the manufacturer’s recommendation. The
concentration of siRNA used was 100nM. After 4 hours of
transfection, the culture medium with serum was added.
The assays were carried out 48 hours post-transfection as
reported earlier [25].
Total RNA isolation and quantitative real time PCR
analysis
Total RNA from cultured NSCLC cells was isolated and
diluted with RNase-free water to 100 ng/mL; then, 10 μl of
each sample were reverse transcribed into complementary
DNA (cDNA) as reported earlier [22]. In brief, after the re-
verse transcription reaction, 80 μl of RNase free water were
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product were mixed with 25 μl of SYBR Green JumpStart
Taq ReadyMix, 0.5 μl of internal reference dye, and 2.0 μl
of specific oligonucleotide primers to a total volume of
50 μl for quantification of the real time polymerase chain
reaction (PCR) (Table 1). The quantification of real-time
PCR was performed by using the SYBR Green method on
the Applied Biosystems 7500 Real Time PCR System with
the following profile: 1 cycle at 94°C for 2 minutes; 40
cycles at 94°C for 15 seconds, at 60°C for 1 minute, and at
72°C for 1 minute for the elongation step. The real-time
PCR products were confirmed by electrophoresis on 2%
agarose gels. Data analysis was carried out by using the ABI
sequence-detection software using relative quantification.
The threshold cycle (Ct), which was defined as the cycle at
which PCR amplification reaches a significant value was
expressed as the mean value. The relative expression of
messenger RNA (mRNA) was calculated by using the ΔCt
method (where ΔCt was the value obtained by subtracting
the Ct value of the housekeeping gene β-actin mRNA from
the Ct value of the target mRNA). The amount of the target
relative to β-actin mRNA was expressed as 2 -(ΔCt).
Western blot analysis
NSCLC cells were cultured in 60 mm size cell culture
dishes (Fisher Scientific, Pittsburgh, VA) to confluence
and the cells were lysed in lysis buffer with the method
reported earlier [26]. Protein was estimated by BCA
method (PIERCE, Rockford, IL) and equal amount of
protein (20 μg/lane) were loaded. Proteins in the sample
were separated in denaturing sodium dodecyl sulphate
(SDS) polyacrylamide gels (Bio-Rad), and transferred
electrophoretically onto polyvinylidene difluoride mem-
brane (Immobilon-P, Millipore, Bedford, MA). The blots
were blocked with 5% Blotting Grade Blocker Non-fat
Dry milk (Bio-Rad, Hercules, CA) for 1 hr on shaker at
room temperature, and were overnight incubated at 4°C
with respective antibodies - rabbit EphA2 antibody,
rabbit cdx-2 antibody (Cell signaling, Beverly, CA) and
rabbit claudin-2 antibody (Invitrogen, Grand Island,
NY), at 1:1000 dilutions. After washing, they were
incubated with the secondary antibody (horseradish
peroxidase-conjugated goat anti-rabbit IgG Ab) at a
dilution of 1:1000 for 1 hr. Finally respective proteins
were detected by enhanced chemiluminescence (ECL,
Amersham Pharmacia Biotech). The Molecular massTable 1 Primers Used in Quantitative Reverse Transcriptase-P




18srRNA AAACGGCTACCACATCCAAG(kDa) of the proteins was determined using the pre-
stained protein marker (Bio-Rad).NSCLC cell proliferation
NSCLC cell proliferation was assessed by using an assay
based on cleavage of the tetrazolium salt WST-1 to
formazan by cellular mitochondrial dehydrogenases
(Roche, Indianapolis, IN) as reported earlier [22]. With
this assay, an increase in the number of viable cells
results in an increase in the overall activity of the mito-
chondrial dehydrogenases in the sample. The augmenta-
tion in enzyme activity leads to an increase in the
formazan dye formed. The formazan dye formed was
quantified by using a plate reader at 450 nm. A549 cells
were plated in 96-well microplate at a density of 0.5 X
105 cells per well. The cells were transfected with
pcDNA-EFNA1, pcDNA-EphA2, siRNA for EphA2 or
with scrambled siRNA (sc-siRNA), cdx-2-siRNA by
using lipofectamine-2000 reagent, and a few wells were
left untreated. The negative controls received serum-free
media, and some of the wells were activated with recom-
binant ephrin-A1. Cells were allowed to incubate for 48
hours. Then, the WST-1 reagent was applied for 4 hours
to measure cell proliferation. The cell proliferation was
assessed in triplicate. The data are presented as a per-
centage of negative control proliferation with P values
<0.05 were considered significant.Immunofluorescence microscopy
Claudin-2 expression in NSCLC cells was analyzed
by using confocal laser-scanning microscopy (Zeiss LSM
510, Axiovert 100 M; Zeiss, Thornwood, NY), as
reported previously [22]. In brief, the cells were cultured
to confluence on gelatinized glass cover slips and fixed
in 5% paraformaldehyde (with 50 mM phosphate buffer)
in 50% Tris wash buffer (TWB). The glass cover slips
were rinsed 3 times and permeabilized with 1.2% Triton
X-100 for 5 minutes, rinsed 3 times, incubated with 1%
bovine serum albumin (BSA) in 100% TWB for 1 hour,
then stained for the expression claudin-2 using primary
antibody rabbit anti-claudin-2 at 1:150 dilution and
secondary antibody goat anti-rabbit immunoglobulin
G conjugated with fluorescein isothiocyanate (FITC)
(Zymed Laboratories, San Francisco, CA). 4, 6-diamino-
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A 48-well culture plate was coated with 200 μl of matrigel
per well and then allowed to polymerize for about 1–2
hours at 37°C. NSCLC cells at a density of ~1 x 103 cells
per well were plated in 0.3 ml of 2% FBS containing RPMI-
1640 as reported earlier [24]. The cells were activated with
ephrin-A1 or transfected with plasmid pcDNA-EphA2 or
pcDNA-EFNA1 or siRNA for EphA2 or cdx-2 or empty
vector by using lipofectamine-2000 and few wells were left
untreated as controls, media were changed every three
days. The number of colonies formed was recorded after
7 days of incubation. 4–6 randomly chosen fields (x10)
from the sample were photographed.Statistical analysis
The Sigma Stat 3.5 statistical software program was used
to calculate statistical significance. Kruskal-Wallis One
Way Analysis of Variance (ANOVA) was used to com-
pare the experimental groups from the control groups.
The post hoc test Holm-Sidak method was applied for
pairwise comparisons. The differences at p < 0.05 were
considered statistically significant.Results
NSCLC cells express receptor EphA2 and Caludin-2
Proliferating NSCLC cells (A549, H2126, H838, H522, and
H23) expressed receptor EphA2, and claudin-2 and the
expression of ephrinA1 was variable (Figure 1A). Receptor
EphA2 was over expressed in all the five NSCLC cell lines
tested. However highest expression of claudin-2 was
noticed in A549, H838 and H23 cell lines when compared
to H2126 and H522 cell lines. Whereas, the expression of
ephrin-A1 was dysregulated. A549, H2126 and H838 cells
showed decreased expression of ephrin-A1 when compared
to H522 and H23 (Figure 1A). In addition NSCLC cells
were transiently transfected with vector containing ephrin-
A1 construct (pcDNA-EFNA1) or empty vector and the ex-
pression of receptor EphA2 was determined in all NSCLC
cell lines selected. Ephrin-A1 activation down regulated the
expression of EphA2 when compared to empty vector
transfected NSCLC cells (Figure 1B). In addition, A549 cells
were also activated with recombinant ephrin-A1 for varying
time (5, 10, 30, 60 and 120 minutes) and the activation/
phosphorylation of receptor EphA2 was evaluated. Ephrin-
A1 activation induced phosphorylation of receptor EphA2
up to 60 minutes in A549 cells. However, at 120 minutes
the phosphorylation was down regulated. The total receptor
expression was comparatively decreased when compared to
control at 120 minutes (Figure 1C). The EphA2 signaling
pathway activation was also determined by evaluating Erk1/
Erk2 activation in NSCLC. EphrinA1 activation inhibited
the phosphorylation of Erk1/Erk2 MAPK in NSCLC when
compared to control cells (Figure 1C).Ephrin-A1 down regulated claudin-2 expression in NSCLC
cells
Ephrin-A1 activation of receptor EphA2 down regulated
the expression of claudin-2 in NSCLC cells. To identify
whether decrease in claudin-2 expression is directly due
to decrease in EphA2 receptor expression, A549 cells
were transfected with pcDNA-EFNA1 or empty vector
or left untransfected. In comparison to empty vector the
transient transfection of A549 cells with pcDNA-EFNA1
resulted in significantly decreased claudin-2 expression
(Figure 2A). This suggested that activation of receptor
EphA2 with the ligand ephrin-A1 induced rapid reduc-
tion of claudin-2 expression that plays a major role in
maintaining cellular integrity. In addition the expression
of claudin-2 and receptor EphA2 was also evaluated by
Western blot analysis. The decreased expression of re-
ceptor EphA2 further confirmed that treatment of A549
cell with ephrin-A1 down regulates the expression of re-
ceptor EphA2 and claudin-2 (Figure 2C, -2D). These
data suggests that ephrin-A1 treatment inhibits the ex-
pression of oncogenic protein EphA2 and claudin-2 in
NSCLC cells.
In order to determine if over expression of the receptor
EphA2 in A549 cells promotes claudin-2 expression, A549
cells were transiently transfected with pcDNA-EphA2 and
the expression of claudin-2 was evaluated. A significant in-
crease in the expression of claudin-2 was noted when com-
pared to empty vector transfected cells (Figure 2B and C).
To investigate whether this increase in claudin-2 expression
was directly due to the increases in EphA2 receptor expres-
sion, NSCLC cells were transfected with EphA2-siRNA. In
A549 cells, silencing the EphA2 receptor with siRNA sig-
nificantly reduced the claudin-2 expression when compared
to sc-siRNA transfected cells (Figure 2B and C). These
results suggest that increased EphA2 expression modulated
claudin-2 expression, which may play an important role in
tumor growth in NSCLC.
Claudin-2 expression decreased in Ephrin-A1 treated
A549 cells
In order to evaluate the cellular distribution of caludin-2,
and morphological changes in activated cells, A549 cells
were activated with ephrin-A1 and analyzed by immuno-
fluorescence microscopy. Fluorescence immuno-staining
analysis revealed that A549 cells showed punctuated
expression of claudin-2 whereas, ephrin-A1 activation
decreased claudin-2 expression (Figure 2E). In cells
transfected with pcDNA-EFNA1 a marked decrease in
claudin-2 expression was noticed. In addition, ephrin-A1
activated cells showed distorted cytoskeleton, and rounded
morphology. However, in cells transfected with pcDNA-
EphA2 a dense and higher expression of claudin-2 was
noticed when compared to control and empty vector
transfected cells. These data suggests that over expression
Figure 1 NSCLC cells express receptor EphA2, Ephrin-A1 and Caludin-2. Plate A: NSCLC cell lines (A549, H2126, H838, H522, H23) express
receptor EphA2, ephrin-A1, and claudin-2. Expression of EphA2, ephrin-A1, and claudin-2 was analyzed by Western blot analysis. Plate B: Western
blot analysis of EphA2 protein expression the β-actin was probed to demonstrate equal sample loading. NSCLC cell lines were either transfected
with pcDNA-EFNA1 (pcDNA-EFNA1 is vector containing ephrin-A1 construct) or empty vector and receptor EphA2 expression was analyzed.
Plate C: A549 cells were activated for 5 minutes to 120 minutes with ephrin-A1. Western blot analysis of phosphorylated EphA2 and Erk1/Erk2 was
performed, the β-actin was probed to demonstrate equal sample loading. Data presented is the representative of three separate experiments.
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in NSCLC cells. Ephrin-A1 activation or transfection of
cells with plasmid containing the ephrin-A1 construct
inhibits the expression of claudin-2 confirming its anti-
tumor effects on NSCLC cells.
Ephrin-A1 treatment increased cdx-2 expression in NSCLC
cells
Cdx-2 a tumor suppressor gene, found to be tissue specific
in its expression. Ephrin-A1 activation induced more than
five folds increases in cdx-2 mRNA expression in NSCLC
cells (Figure 3A). In addition this expression was also con-
firmed in the cells transfected with plasmid containing
ephrin-A1 construct pcDNA-EFNA1. The transfection with
pcDNA-EFNA1 also showed a significant increase of cdx-2
expression in A549 cells when compared to empty vector
(Figure 3A). Furthermore, the cells were also transfected
with plasmid pcDNA-EphA2 or empty vector and the ex-
pression of cdx-2 was evaluated. A remarkable reduction in
the expression of cdx-2 was noticed in cells transfected with
pcDNA-EphA2. However, knockdown of EphA2 gene with
siRNA-EphA2 significantly upregulated the expression of
cdx-2 in A549 cells when compared to sc-siRNAtransfected cells (Figure 3B). These results suggest that un-
regulated/lost expression of cdx-2, a tumor suppressor gene
may result to increased EphA2 expression in A549 cells.
Furthermore cdx-2 expression with activation of ephrin-A1
or transfection with pcDNA-EFNA1 or PcDNA-EphA2 in
A549 cells was also confirmed with Western blot analysis
(Figure 3C). These data suggests that activation of receptor
with ephrin-A1 up regulates the expression of tumor sup-
pressor gene cdx-2. Silencing the expression of EphA2
receptor also increases the expression of cdx-2 which indi-
cates that knockdown of EphA2 either by ephrin-A1 activa-
tion or by silencing interference RNA could be potential in
inhibiting the oncogenic effect of receptor EphA2 and
tumor growth.
Silencing cdx-2 expression blocked ephrin-A1 mediated
inhibition of claudin-2 expression in NSCLC cells
Activation of A549 cells with ephrin-A1 or transfection
with pcDNA-EFNA1 resulted in significant decrease of
claudin-2 expression. In addition over expression of cdx2
by using pcMV-cdx-2, a plasmid with cdx2 construct
resulted in significant decrease of claudin-2 expression
(Figure 4A and B). Moreover, when A549 cells were
Figure 2 (See legend on next page.)
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Figure 2 Ephrin-A1 activation decreases claudin-2 expression in NSCLC cells. Relative expression of claudin-2 mRNA normalized to
endogenous control. Plate A: Cells were either activated with ephrin-A1 or transfected with pcDNA-EFNA1 (vector containing Ephrin-A1
construct) or empty vector. Plate B: Cells either silenced with EphA2 siRNA or transfected with pcDNA-EphA2 (pcDNA-EphA2 is vector containing
EphA2 construct) Plate C: Claudin-2 protein expression by Western blot analysis, β-actin was probed to demonstrate equal sample loading.
Plate D: Western blot analysis of EphA2 protein expression the β-actin was probed to demonstrate equal sample loading. Data presented was the
mean± SEM of three independent experiments, *p < 0.001 compared to control; #p < 0.001 compared to empty vector; $p < 0.001 compared to
sc-siRNA. Plate E: Claudin-2 expression in NSCLC as observed by immunofluorescence analysis. The photomicrographs show immunofluorescence
staining of claudin-2 in NSCLC. Blue colour represents the nuclear stain DAPI (4,6-diamino-2-phenylindole), Red colour represents Rhodamin
phalloidin for F-actin filament stain, and green colour represents Alexa Flour 488 labelled for claudin-2 expression. The data presented is a single
representative of three similar observations Scale Bar = 40 μm.
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the expression of claudin-2 expression was significantly
upregulated (Figure 4A). Furthermore Immunofluorescence
staining for the expression of claudin-2 also confirmed thatFigure 3 Transfection of pcDNA-EFNA1 increased whereas transfectio
Plate A: cells were either activated with ephrin-A1 or transfected with pcDN
Cdx-2 mRNA expression was analyzed by quantitative real time PCR. Plate B
pcDNA-EphA2 (pcDNA-EphA2 is vector containing EphA2 construct) Plate C
probed to demonstrate equal sample loading. The Western blot represents
independent experiments. *p < 0.001 compared to control, #p < 0.001 compsilencing cdx-2 gene and activation with ephrin-A1 resulted
in enhanced expression of claudin-2 (Figure 4C). Our
results suggest that EphA2 signaling promoted claudin-2
expression in A549 cells and downregulated the expressionn of pcDNA-EphA2 attenuated cdx-2 expression in NSCLC cells.
A-EFNA1 (pcDNA-EFNA1 is vector containing ephrin-A1 construct).
: Cells either silenced with EphA2 siRNA or transfected with
: Western blot analysis of claudin-2 protein expression, the β-actin was
three similar observations. Data presented is the mean± SEM of three
ared to Empty vector, $p < 0.001 compared to sc-siRNA.
Figure 4 Silencing cdx-2 expression restores Ephrin-A1 mediated inhibition of Claudin-2 expression in NSCLC cells. Plate A: Relative
mRNA expression of claudin-2 normalized to endogenous control. (pcDNA-EFNA1 is vector containing ephrin-A1 construct). Plate B: Claudin-2
expression was analyzed by Western blot, data represents mean± SEM of three independent experiments. *p < 0.001 compared to control,
# p< 0.001 compared to Empty vector, $p < 0.001 compared to cdx2-siRNA alone. **p < 0.001 compared to control. Plate C: Immunofluorescence
analysis of claudin-2 expression in NSCLC. Blue colour represents the nuclear stain DAPI (4, 6-diamino-2-phenylindole), Red colour represents
Rhodamin phalloidin for F-actin filaments, and green colour represents Alexa Flour-488 labelled for claudin-2 expression. The data presented is a
single representative of three similar observations. Scale Bar = 40 μm.
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that ephrin-A1 mediated down regulation of claudin-2 ex-
pression in A549 cells is dependent on cdx-2.
Silencing cdx-2 expression blocked Ephrin-A1 mediated
inhibition of cell proliferation in NSCLC cells
Ephrin-A1 activation and transfection with ephrin-A1 vec-
tor pcDNA-EFNA1 resulted in suppression of prolifera-
tion in A549 cells when compared to control or empty
vector transfected cell (Figure 5A). Silencing of EphA2receptor by EphA2-siRNA also showed decreased cell pro-
liferation as compared to sc-siRNA or control (Figure 5B).
In addition, the cells were transfected with pcDNA-EphA2
that showed a significant increase in proliferation when
compared to empty vector or control cells. However, when
cells were transfected with cdx2-siRNA and subsequently
activated with ephrin-A1 the proliferation of cells was
restored and showed close to control cell proliferation
rate. Moreover, knockdown of cdx-2 with siRNA and
transient transfection with pcDNA-EFNA1, resulted in
Figure 5 Ephrin-A1 activation attenuates NSCLC cell proliferation. Proliferation of NSCLC cells as measured by WST-1 assay. Plate A:
Proliferation in cells either activated with ephrin-A1 or transfected with pcDNA-EFNA1 (pcDNA-EFNA1 is vector containing ephrin-A1 construct).
Plate B: Proliferation in cells either silenced with EphA2 siRNA or transfected with pcDNA-EphA2 (pcDNA-EphA2 is vector containing EphA2
construct). Plate C: Proliferation in cdx-2 siRNA transfected cells that were treated with ephrin-A1 ligand or pcDNA-EFNA1 transfected. Data
presented is the mean± SEM of three independent experiments. *p < 0.05 compared to control; $ p < 0.05 compared to ephrin-A1 or
pcDNA-EFNA1 alone, # p < 0.001 compared to empty vector or sc-siRNA+ ephrinA1, NS is not significant.
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pcDNA-EFNA1 transfected cells (Figure 5A, -5C). The
transfection of cdx-2-siRNA alone showed slight increase
in the proliferation rate but was not significant when com-
pared with control. These results suggest that ephrin-A1
induced increased expression of cdx-2 suppressed prolif-
eration of NSCLC. The transfection of NSCLC with cdx2-
siRNA followed by ephrin-A1 activation blunted ephrin-
A1 mediated inhibition of A549 cell proliferation.
Ephrin-A1 activation inhibited tumor growth and
silencing cdx-2 expression blunted Ephrin-A1 mediated
suppression of tumor growth in NSCLC cells in vitro
A549 cells were activated with eprhin-A1 or transfected
with a plasmid pcDNA-EFNA1, or empty vector, or leftuntransfected as control. The transfected or control cells
were plated on 3-D matrigels to determine the tumor
growth in vitro. The tumor growth was studied for
2 weeks. Microscopic examination revealed that A549
cells activated with ephrin-A1 and those transfected with
pcDNA-EFNA1 showed suppressed tumor growth in
matrigel as compared to empty vector transfected or
control cells (Figure 6). In contrast NSCLC cells trans-
fected with pcDNA-EphA2 showed aggressive tumor
growth which was significantly larger in size as com-
pared to tumors grown after silencing the EphA2 with
siRNA. In addition, when the A549 cells were trans-
fected with cdx-2 siRNA and subsequently treated with
the ephrin-A1 or transfected with pcDNA-EFNA1 we
noticed significantly increased tumor formation as
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and pcDNA-EFNA1 transfected cells (Figure 6). Taken
together these results indicate that when A549 cells
transfected with pcDNA-EphA2 to over expressed
receptor EphA2 increased claudin-2 expression was
observed which promoted the A549 cell proliferation.
Activation of NSCLC cells with ephrin-A1 leads to
tumor growth inhibition via cdx-2 expression.
Discussion
The major finding of our present study is that receptor
EphA2 is over expressed in NSCLC cell lines which pro-
motes tumor growth. In addition we also found that
EphA2 promotes tight junction protein claudin-2 ex-
pression in A549 cells. However, the expression of
ephrin-A1 was found to dysregulated and A549 cells
showed minimal levels. There is accumulating evidence
that activation of receptor EphA2 with its ligand ephrin-
A1 attenuates tumorogenic potential of malignant cells
[24,27,28]. The molecular mechanisms responsible for
tumor suppressive effects of ephrin-A1 are still elusive.
In the present study, we report that proliferating NSCLC
cells showed enhanced expression of EphA2, and clau-
din-2. The activation of receptor EphA2 with ephrin-A1Figure 6 Ephrin-A1 ligand activation decreases tumor growth in NSCL
treatments as described and after 7 days of culture tumor growth was reco
data presented are a single representative of three similar but independeninhibited the expression of EphA2 and claudin-2. To fur-
ther examine the effect of ephrin-A1 on NSCLC we
transfected the cells with vector expressing ephrinA1
construct, pcDNA-EFNA1. We found that forced ex-
pression of ephrin-A1 down regulated the receptor
EphA2 and inhibited cell proliferation and tumor growth
in 3D matrigel. In addition the activation of receptor
EphA2 with ephrin-A1 induced phosphorylation of
EphA2 and inhibited the downstream singling MAP
kinase pathway Erk1/Erk2. Furthermore, the activation
of EphA2 receptor with ephrinA1 induced cdx-2, a
tumor suppressor gene in A549 cells. These data
suggests that ephrin-A1 activation/transfection could
effectively bind and activate endogenous EphA2 in
NSCLC and led to internalization and degradation of
EphA2. In order to understand if receptor EphA2 signal-
ing modulates TJ protein claudin-2 we transfected the
A549 cells with EphA2 expressing vector, pcDNA-
EphA2. The expression of claudin-2 was higher in A549
cells transfected with pcDNA-EphA2 as compared to
empty vector transfected cells or control cells. In
addition, over expression of receptor EphA2 significantly
enhanced tumor growth. Whereas silencing the expres-
sion of receptor EphA2 by siRNA, decreased theC. Equal number of A549 cells was seeded in matrigels after various
rded by a SPOT digital camera attached to Nikon microscope. The
t experiments. Magnification= 5 μM.
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up-regulation of cdx-2 was noticed in NSCLC cells as
compared to sc-siRNA transfected A549 cells. However,
silencing cdx-2 gene with siRNA and subsequent activa-
tion with ephrin-A1 or transfection with pcDNA-EFNA1
failed to inhibit tumor growth in A549 cells. Collectively
these data suggests that an ephrin-A1 mediated
anti-oncongenic effect is due to downregulation of
EphA2, claudin-2 expression and induction of cdx-2
gene in NSCLC.
EphA2 is an oncoprotein which promotes cell survival,
abnormal cell growth and invasion in a number of
malignancies, including NSCLC [18,20,21,29]. In malig-
nant cells such as A549, due to dysregulated cell division
and abnormal growth the cell-cell contacts are loose
which hinders the interaction between neighbouring
cells. The loss of contact among the adjacent cells
results in accumulation of high levels of intracellular
EphA2 and claudin-2 an integral component of tight
junction. Tight junctions are the apical cell-cell adhe-
sions that regulate paracellular permeability and are
critical for cell polarity. Alteration in tight junction
protein claudin-2, can cause the defects in normal regu-
lation of growth factor receptor activation due to a dif-
ferential distribution of the receptor and their respective
ligands, which can be observed with respect to receptor
EphA2 and its ligand Ephrin-A1 [30]. In this study, we
attempted to understand the underlying mechanisms by
which EphA2 over expression leads to enhanced or ir-
regular claudin-2 expression via cdx-2 modulation and
promote tumor growth in NSCLC cells. Several studies
reported that receptor EphA2 is over expressed in a
number of malignancies [19,20,30]. Previously we have
reported that EphA2 is over expressed in malignant
mesothelioma cells (MMC) and posttranslational silen-
cing of EphA2 significantly suppresses the proliferation
and haptotactic migration of MMC [22,24]. In addition,
EphA2 receptor activation in MMC by its ligand ephrin-
A1 inhibited the RAS MAP kinase signaling pathways
[23,24]. Our study in A549 cells revealed that receptor
EphA2 signaling up regulates the TJ protein claudin-2.
In turn, the over expression of claudin-2 along with
EphA2 promotes A549 cell proliferation and tumor
growth. It was reported that EGF signaling induced
claudin-2 expression which promoted colonization of
mammary tumor cells [31]. The up regulated levels of
claudin-2 caused leaky cellular barriers in MDCK1 cells
[32]. The junctional claudin-2 forms the selective cation
channels that are sufficient to transform the functional
“tight” junction into a “leaky” one [33]. The leaky
barriers may contribute to increase uptake of nutrients
and growth factor which promote exaggerated tumor
colonization. In the present study we noted exaggerated
tumor colonies formation when EphA2 was overexpressed in A549 cells. It is plausible that over expres-
sion of receptor EphA2 promotes claudin-2 which in
turn enhances tumor colonization of A549 cells.
We demonstrate that activation of receptor EphA2
with ephrin-A1 induced cdx-2 expression and inhibited
tumor formation. The over expression of cdx-2 by vector
pcMV-cdx-2 resulted in downregulation of claudin-2
and attenuation of cell proliferation and tumor growth
on matrigels. In addition silencing cdx-2 expression
using siRNA and activation with eprhin-A1 resulted in
up regulation of claudin-2 in A549 cells. Cdx-2, a tumor
suppressor gene is homeobox transcriptional factor that
is known to control apical-basolateral polarity in mouse
enterocytes and human colonic epithelial cells [34].
Cdx-2 regulates epithelial cell polarity and morphogen-
esis through control of apical protein transport. At the
transcriptional level, transcriptional factors such as
cdx-2 can bind to the promoter regions of various clau-
din genes and affect their expression [1,10]. In addition,
certain characteristics of claudin-2 and cdx-2 show simi-
larity that both are critical for epithelial cell polarity
[1,34]. Increased cdx-2 expression was used as a marker
for progression in gastric carcinogenesis [35], while
some of the gastric cancers studies showed aberrant ex-
pression of cdx-2 in intestinal metaplasia which is a sub-
set of gastric adenocarcinoma [36]. The down-regulation
of cdx-2 mechanism was related to the induction of
ulcer-associated cell lineage (UACL) [37]. In addition
loss of cdx-2 immunoreactivity was implicated as diag-
nostic feature in poorly differentiated colorectal adeno-
carcinoma [38]. Whereas, the reduced expression of
cdx-1 and cdx-2 genes were associated with the develop-
ment of enterocolitis in intestinal mucosa [39]. Further-
more, activation of Ras oncogene was associated with
down regulation of the cdx-2 in colon cancer cells [40].
All these studies confirm that expression of cdx-2 gene
though disease specific and tissue specific, the expres-
sion of cdx2 was directly associated with tumor growth.
The plausible mechanisms for the reduced cdx-2 expres-
sion in carcinogenesis, could be that homeodomain pro-
teins signifies roles in directing the cells to specified
cell-phenotype during organogenesis in early stages of
development. However, a reduction of cdx-2 gene ex-
pression in the late stages such as in invasive tumors
may be attributed to over expression oncogenic proteins
which may lead to deviate from normal epithelial pheno-
type to the neoplastic phenotype [15].
It has been shown that, caudal-related homeobox gene
cdx-2 is positively involved in the regulation of the
human claudin-2 promoter activity [17]. The EphA2 sig-
naling caused reduced expression of transcription factor
cdx-2 that hinder its binding to claudin promoter and
thus cause irregular expression of claudin-2 which is
reported to be increased in NSCLC cells in the present
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claudin-2 there is a disruption in epithelial cell polarity
leading to leakage of large solutes passing across epithe-
lial barriers to the other cells. Thus, the TJ disruption in
premalignant neoplastic tissue can increase the proba-
bility that it will develop into a complete carcinoma be-
cause of the continuous stimulation of cell division fol-
lowed by disrupted natural barriers between growth
factors and their receptors. The novel finding of our
present study is that receptor EphA2 mediated the
enhanced induction of functionally altered claudin-2 via
down-regulation of tumor suppressor gene expression
cdx-2 in NSCLC cells. It is possible that activation of
receptor EphA2 with ephrin-A1 downregulated claudin-
2 and induced the expression of cdx-2 suggesting
oncogenic protein EphA2 play a major role in regulating
cdx-2 expression in NSCLC. Whereas, the forced ex-
pression of ephrin-A1 induced tumor suppressive signals
via downregulation and degradation EphA2 and inhib-
ited the oncogenic singling pathway in NSCLC. How-
ever, this needs to be further investigated.
Conclusions
In conclusion, we present the first evidence that EphA2
signaling promotes the expression of claudin-2 in NSCLC
cells. Activation of NSCLC with ligand ephrin-A1 sup-
pressed the caludin-2 expression via the induction of tran-
scriptional factor cdx-2. These studies suggest that
targeting EphA2 by using ephrin-A1 may be a promising
approach for the therapeutic inventions against NSCLC.
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